Glenmark Pharmaceuticals has submitted an NDA for Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in patients aged 12 and older, the company said.
Glenmark Pharmaceuticals President and Chief Medical Officer Fred Grossman said, “Our first NDA submission with Ryaltris is the culmination of years of diligent effort by our employees and clinicians. This is an important milestone for Glenmark, and another step in our rapid transition into becoming an innovation-led and discovery-driven life sciences company.”
Read the Glenmark press release.
